Medical/Pharmaceuticals
Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma
The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its op...
2024-03-06 08:45
2041
Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...
2024-03-06 08:30
2328
Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024
* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...
2024-03-06 05:30
2019
Datasea Expects Approximately 1,128% Revenue Growth in 2024
BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...
2024-03-05 23:45
3016
Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production
IRVINE, Calif., March 5, 2024 /PRNewswire/ -- In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A ( PureRec RNase A), a challenge that persisted for over half a century. This breakthroug...
2024-03-05 22:00
1587
DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador
Expansion would make DaVita the largest dialysis services provider in Latin America DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations inBrazil and ...
2024-03-05 22:00
3825
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environ...
2024-03-05 21:00
1679
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
GAITHERSBURG, Md., March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2024-03-05 21:00
2815
IRBM Expands Global Reach in Drug Discovery with New Boston Office
Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...
2024-03-05 20:24
1965
One Million Global Healthcare Seekers Embrace MedicalTourism.com: Medical Tourism Magazine Leads the Way
WEST PALM BEACH, Fla., March 5, 2024 /PRNewswire/ -- Launched in 2023 by The Medical Tourism Association, DarwinAI (Artificial Intelligence) is an AI-enabled marketing technology revolutionizing the medical tourism landscape. Darwin AI uses powerful AI-enabled algorithms to drive brand awareness,...
2024-03-05 16:00
1685
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2024-03-05 13:35
2445
First Patient Treated in Phase 2 GvHD Trial
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial ofCYP-001...
2024-03-05 10:08
1794
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
MELBOURNE, Australia, March 5, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manuf...
2024-03-05 07:01
1722
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
TAIPEI, March 4, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TWO) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-opera...
2024-03-05 06:55
1583
Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024
- Showcases brain imaging analysis technology with key products Neurophet AQUA and Neurophet SCALE PET - Aims to commercialize ARIA analysis and amyloid-positive prediction technology SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company f...
2024-03-04 22:00
1581
ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers
NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to supportex vivo cell manufacturing and manufacturers of innovative cell and gene therapies. I...
2024-03-04 22:00
1370
Cyient Partners with MassMedic to Accelerate MedTech Innovation
HYDERABAD, India, March 4, 2024 /PRNewswire/ -- Cyient, a global Intelligent Engineering and Technology Solutions company, is thrilled to announce its membership with the Massachusetts Medical Device Industry Council (MassMedic), the largest regional MedTech association inthe United States. This ...
2024-03-04 22:00
1408
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
SHANGHAI, March 4, 2024 /PRNewswire/ -- Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited consolidated management accounts for the year ended31 December, 2023 (the "Reporting Period") and the information currently available to the Board,it...
2024-03-04 21:19
2357
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has officially approved the YOLT-2...
2024-03-04 20:00
747
Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
MANCHESTER, England, March 4, 2024 /PRNewswire/ -- Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a$42M Series D financing all equity investment round. The combined European andUnited States investment sy...
2024-03-04 20:00
1276
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685